11-Feb-2026
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Jan 6:00 AM ET)
Globe Newswire (Mon, 12-Jan 6:00 AM ET)
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Globe Newswire (Sun, 11-Jan 6:00 PM ET)
Globe Newswire (Tue, 6-Jan 1:34 PM ET)
Zymeworks Announces Participation in Upcoming Conferences
Globe Newswire (Tue, 2-Dec 4:05 PM ET)
Globe Newswire (Tue, 18-Nov 8:45 AM ET)
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Globe Newswire (Tue, 18-Nov 1:01 AM ET)
Globe Newswire (Tue, 18-Nov 1:00 AM ET)
Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open
Globe Newswire (Mon, 17-Nov 10:48 AM ET)
Zymeworks’ Phase 3 Results Point to Ziihera as Potential New Standard of Care in HER2-Positive GEA
Market Chameleon (Mon, 17-Nov 5:31 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of February 11, 2026, ZYME stock price climbed to $22.83 with 412,950 million shares trading.
ZYME has a beta of 0.83, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.07 to the broad based SPY ETF.
ZYME has a market cap of $1.72 billion. This is considered a Small Cap stock.
Last quarter Zymeworks reported $28 million in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.05.
In the last 3 years, ZYME traded as high as $28.49 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a return of +60.9%, while the SPY ETF gained +15.6%. In the last 3 month period, ZYME beat the market returning +26.5%, while SPY returned +1.8%. However, in the most recent 2 weeks ZYME has underperformed the stock market by returning -1.8%, while SPY returned -0.5%.
ZYME support price is $22.10 and resistance is $23.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.